Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation

References

• Artalejo CR, Lemmon MA, Schlessinger J, Palfrey HC. 1997. Specific role for the PH domain of dynamin-1 in the regulation of rapid endocytosis in adrenal chromaffin cells. EMBO J. 16:1565–1574.
   PubMedGoogle Scholar
• Barbieri MA, Fernandez-Pol S, Hunker C, Horazdovsky BH, Stahl PD. 2004. Role of rab5 in EGF receptor-mediated signal transduction. Eur J Cell Biol. 83:305–314.
   PubMedGoogle Scholar
• Bild AH, Turkson J, Jove R. 2002. Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J. 21:3255–3263.
   PubMedGoogle Scholar
• Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JEJr. 1999. Stat3 as an oncogene. Cell. 98:295–303.
   PubMed Web of Science ®Google Scholar
• Budd DC, Rae A, Tobin AB. 1999. Activation of the mitogen-activated protein kinase pathway by a Gq/11-coupled muscarinic receptor is independent of receptor internalization. J Biol Chem. 274:12355–12360.
   PubMedGoogle Scholar
• Buettner R, Mora LB, Jove R. 2002. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 8:945–954.
   PubMed Web of Science ®Google Scholar
• Burgess AW. 2008. EGFR family: Structure physiology signalling and therapeutic targets. Growth Factors. 26:263–274.
   PubMed Web of Science ®Google Scholar
• Damke H, Baba T, Warnock DE, Schmid SL. 1994. Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol. 127:915–934.
   PubMed Web of Science ®Google Scholar
• Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. 2003. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol. 5:410–421.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Settleman J. 2008. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev. 18:73–79.
   PubMed Web of Science ®Google Scholar
• Gorska MM, Cen O, Liang Q, Stafford SJ, Alam R. 2006. Differential regulation of interleukin 5-stimulated signaling pathways by dynamin. J Biol Chem. 281:14429–14439.
   PubMedGoogle Scholar
• Grandal MV, Madshus IH. 2008. Epidermal growth factor receptor and cancer: Control of oncogenic signalling by endocytosis. J Cell Mol Med. 12:1527–1534.
   PubMed Web of Science ®Google Scholar
• Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS. 2007. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis. 28:1408–1417.
   PubMed Web of Science ®Google Scholar
• Han W, Zhang T, Yu H, Foulke JG, Tang CK. 2006. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther. 5:1361–1368.
   PubMed Web of Science ®Google Scholar
• Hill T, Odell LR, Edwards JK, Graham ME, McGeachie AB, Rusak J, Quan A, Abagyan R, Scott JL, Robinson PJ, McCluskey A. 2005. Small molecule inhibitors of dynamin I GTPase activity: Development of dimeric tyrphostins. J Med Chem. 48:7781–7788.
   PubMedGoogle Scholar
• Hinshaw JE. 2000. Dynamin and its role in membrane fission. Annu Rev Cell Dev Biol. 16:483–519.
   PubMed Web of Science ®Google Scholar
• Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK. 1997. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 272:2927–2935.
   PubMed Web of Science ®Google Scholar
• Huang F, Khvorova A, Marshall W, Sorkin A. 2004. Analysis of clathrin-mediated endocytosis of epidermal growth factor receptor by RNA interference. J Biol Chem. 279:16657–16661.
   PubMed Web of Science ®Google Scholar
• Hynes NE, MacDonald G. 2009. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 21:177–184.
   PubMed Web of Science ®Google Scholar
• Kermorgant S, Parker PJ. 2008. Receptor trafficking controls weak signal delivery: A strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol. 182:855–863.
   PubMed Web of Science ®Google Scholar
• Kranenburg O, Verlaan I, Moolenaar WH. 1999. Dynamin is required for the activation of mitogen-activated protein (MAP) kinase by MAP kinase kinase. J Biol Chem. 274:35301–35304.
   PubMed Web of Science ®Google Scholar
• Le Roy C, Wrana JL. 2005. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 6:112–126.
   PubMed Web of Science ®Google Scholar
• Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM. 2001. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res. 61:5355–5361.
   PubMed Web of Science ®Google Scholar
• Luwor RB, Zhu HJ, Walker F, Vitali AA, Perera RM, Burgess AW, Scott AM, Johns TG. 2004. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene. 23:6095–6104.
   PubMedGoogle Scholar
• Marks B, Stowell MH, Vallis Y, Mills IG, Gibson A, Hopkins CR, McMahon HT. 2001. GTPase activity of dynamin and resulting conformation change are essential for endocytosis. Nature. 410:231–235.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. 2000. The EGF receptor family as targets for cancer therapy. Oncogene. 19:6550–6565.
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE. 1999. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem. 274:17209–17218.
   PubMedGoogle Scholar
• Orth JD, Krueger EW, Weller SG, McNiven MA. 2006. A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. Cancer Res. 66:3603–3610.
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Pedersen N, Damstrup L, Villingshoj M, Sonder SU, Rieneck K, Bovin LF, Spang-Thomsen M, Poulsen HS. 2005. Analysis of the epidermal growth factor receptor specific transcriptome: Effect of receptor expression level and an activating mutation. J Cell Biochem. 96:412–427.
   PubMed Web of Science ®Google Scholar
• Piazza TM, Lu JC, Carver KC, Schuler LA. 2009. SRC family kinases accelerate prolactin receptor internalization, modulating trafficking and signaling in breast cancer cells. Mol Endocrinol. 23:202–212.
   PubMedGoogle Scholar
• Pomerantz RG, Grandis JR. 2004. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol. 31:734–743.
   PubMed Web of Science ®Google Scholar
• Quan A, McGeachie AB, Keating DJ, van Dam EM, Rusak J, Chau N, Malladi CS, Chen C, McCluskey A, Cousin MA, Robinson PJ. 2007. Myristyl trimethyl ammonium bromide and octadecyl trimethyl ammonium bromide are surface-active small molecule dynamin inhibitors that block endocytosis mediated by dynamin I or dynamin II. Mol Pharmacol. 72:1425–1439.
   PubMedGoogle Scholar
• Ren Z, Schaefer TS. 2002. ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. J Biol Chem. 277:38486–38493.
   PubMed Web of Science ®Google Scholar
• Ringerike T, Stang E, Johannessen LE, Sandnes D, Levy FO, Madshus IH. 1998. High-affinity binding of epidermal growth factor (EGF) to EGF receptor is disrupted by overexpression of mutant dynamin (K44A). J Biol Chem. 273:16639–16642.
   PubMedGoogle Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:183–232.
   PubMed Web of Science ®Google Scholar
• Sehgal PB. 2008. Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol. 19:329–340.
   PubMed Web of Science ®Google Scholar
• Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P, Di Fiore PP, Polo S. 2005. Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA. 102:2760–2765.
   PubMed Web of Science ®Google Scholar
• Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. 2008. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell. 15:209–219.
   PubMed Web of Science ®Google Scholar
• Sorkin A, Goh LK. 2009. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 315:683–696.
   PubMed Web of Science ®Google Scholar
• Sorkin A, von Zastrow M. 2002. Signal transduction and endocytosis: Close encounters of many kinds. Nat Rev Mol Cell Biol. 3:600–614.
   PubMed Web of Science ®Google Scholar
• Sorkin A, von Zastrow M. 2009. Endocytosis and signalling: Intertwining molecular networks. Nat Rev Mol Cell Biol. 10:609–622.
   PubMed Web of Science ®Google Scholar
• Sousa LP, Lax I, Shen H, Ferguson SM, Camilli PD, Schlessinger J. 2012. Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane. Proc Natl Acad Sci USA. 109:4419–4424.
   PubMedGoogle Scholar
• Stenvers KL, Tursky ML, Harder KW, Kountouri N, Amatayakul-Chantler S, Grail D, Small C, Weinberg RA, Sizeland AM, Zhu HJ. 2003. Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol Cell Biol. 23:4371–4385.
   PubMed Web of Science ®Google Scholar
• Tosoni D, Cestra G. 2009. CAP (Cbl associated protein) regulates receptor-mediated endocytosis. FEBS Lett. 583:293–300.
   PubMedGoogle Scholar
• Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, Jove R. 2004. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther. 3:1533–1542.
   PubMed Web of Science ®Google Scholar
• Vieira AV, Lamaze C, Schmid SL. 1996. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science. 274:2086–2089.
   PubMed Web of Science ®Google Scholar
• Wang Y, Robledo O, Kinzie E, Blanchard F, Richards C, Miyajima A, Baumann H. 2000. Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor. J Biol Chem. 275:25273–25285.
   PubMed Web of Science ®Google Scholar
• Warnock DE, Baba T, Schmid SL. 1997. Ubiquitously expressed dynamin-II has a higher intrinsic GTPase activity and a greater propensity for self-assembly than neuronal dynamin-I. Mol Biol Cell. 8:2553–2562.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Saito K, Kinjo M, Matsuda T, Tamura M, Kon S, Miyazaki T, Uede T. 2004. Molecular dynamics of STAT3 on IL-6 signaling pathway in living cells. Biochem Biophys Res Commun. 324:1264–1273.
   PubMed Web of Science ®Google Scholar
• Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG. 1990. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science. 247:962–964.
   PubMedGoogle Scholar
• Xu F, Mukhopadhyay S, Sehgal PB. 2007. Live cell imaging of interleukin-6-induced targeting of “transcription factor” STAT3 to sequestering endosomes in the cytoplasm. Am J Physiol Cell Physiol. 293:C1374–C1382.
   PubMedGoogle Scholar
• Zhu HJ, Iaria J, Orchard S, Walker F, Burgess AW. 2003. Epidermal growth factor receptor: Association of extracellular domain negatively regulates intracellular kinase activation in the absence of ligand. Growth Factors. 21:15–30.
   PubMed Web of Science ®Google Scholar